Kidswell Bio

Kidswell Bio EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Kidswell Bio (4584.T) as of Oct 28, 2026 is -10.90. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 12.57 — a change of -186.71% (lower).

EV/FCF

-10.90

YoY

-186.71%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Kidswell Bio is 2026 -10.90 . EV/FCF (Enterprise Value to Free Cash Flow) of Kidswell Bio was 2025 12.57 . It decreases by -186.71% lower compared to the previous year.

The Kidswell Bio EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-12.58 JPY
Jan 1, 2020
-3,693.26 JPY
Jan 1, 2021
-9.83 JPY
Jan 1, 2022
-10.59 JPY
Jan 1, 2023
-4.83 JPY
Jan 1, 2024
-14.54 JPY
Jan 1, 2025
12.57 JPY
Jan 1, 2026
-10.90 JPY
The Kidswell Bio EV/FCF history
YEAREV/FCFYoY
-10.90-186.71%
12.57-186.43%
-14.54+201.00%
-4.83-54.38%
-10.59+7.77%
-9.83-99.73%
-3,693.26+29,250.40%
-12.58-49.62%
-24.98+319.86%
-5.95-71.77%
-21.07+51.45%
-13.91-15.47%
-16.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kidswell Bio Stock analysis

What does Kidswell Bio do? Kidswell Bio Corp develops biopharmaceutical products, focusing on biosimilar filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The company also researches anti-RAMP2 antibodies for cancer and eye diseases, new antibodies, and regenerative medicine using intracardiac stem cells for pediatric heart conditions and dental pulp stem cells for cleft lip, palate, and intestinal ganglion cell deficiency. Revenue comes from the biosimilar business, new biopharmaceutical business, and new biotechnology business, targeting healthcare providers and medical institutions seeking cost-effective treatments. The biosimilar products include filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The new biopharmaceutical business develops anti-RAMP2 antibodies and new antibodies, while the new biotechnology business focuses on regenerative medicine with stem cell applications. These products are sold to hospitals, clinics, and research institutions requiring advanced biopharmaceutical solutions. Kidswell Bio Corp's revenue streams are derived from the sale of biosimilar products, anti-RAMP2 antibodies, and regenerative medicine solutions. The company targets healthcare providers in oncology, nephrology, ophthalmology, and regenerative medicine sectors. Sales are driven by the demand for affordable alternatives to branded biologics, with a focus on pediatric and chronic disease treatments. Kidswell Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kidswell Bio stock

EV/FCF (Enterprise Value to Free Cash Flow) of Kidswell Bio is -10.90 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Kidswell Bio changed from 12.57 to -10.90, representing a -186.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Kidswell Bio since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Kidswell Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Kidswell Bio

All Key Metrics — Kidswell Bio